Murine myeloid leukemia: in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes

K. Pavelić, M. Sirotković, M. Kopitar, J. Pavelić, S. Vuk-Pavlović

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.

Original languageEnglish (US)
Pages (from-to)123-126
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume19
Issue number1
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Myeloid Leukemia
Leukocytes
Peptide Hydrolases
Insulin
Proinsulin
Cathepsin B
Radioimmunoassay
human CSTA protein
Enzymes
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Murine myeloid leukemia : in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes. / Pavelić, K.; Sirotković, M.; Kopitar, M.; Pavelić, J.; Vuk-Pavlović, S.

In: European Journal of Cancer and Clinical Oncology, Vol. 19, No. 1, 1983, p. 123-126.

Research output: Contribution to journalArticle

Pavelić, K. ; Sirotković, M. ; Kopitar, M. ; Pavelić, J. ; Vuk-Pavlović, S. / Murine myeloid leukemia : in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes. In: European Journal of Cancer and Clinical Oncology. 1983 ; Vol. 19, No. 1. pp. 123-126.
@article{25245552d9004c36891cd5126c92ccff,
title = "Murine myeloid leukemia: in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes",
abstract = "Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.",
author = "K. Pavelić and M. Sirotković and M. Kopitar and J. Pavelić and S. Vuk-Pavlović",
year = "1983",
doi = "10.1016/0277-5379(83)90406-6",
language = "English (US)",
volume = "19",
pages = "123--126",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "1",

}

TY - JOUR

T1 - Murine myeloid leukemia

T2 - in vivo suppression by sericystatin A, a proteinase inhibitor from leukocytes

AU - Pavelić, K.

AU - Sirotković, M.

AU - Kopitar, M.

AU - Pavelić, J.

AU - Vuk-Pavlović, S.

PY - 1983

Y1 - 1983

N2 - Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.

AB - Parenteral administration of sericystatin A, an intracellular leukocyte inhibitor of the proinsulin-splitting enzyme cathepsin B, prolongs the mean survival time of mice with insulin-dependent myeloid leukemia. Sericystatin A reduces the supranormal blood levels of substances detectable by insulin-specific radioimmunoassay in these animals; this effect is abolished by concomitant insulin administration. It is concluded that sericystatin A reduces tumor proliferation indirectly, i.e. by reducing circulating insulin levels.

UR - http://www.scopus.com/inward/record.url?scp=0020694075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020694075&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(83)90406-6

DO - 10.1016/0277-5379(83)90406-6

M3 - Article

C2 - 6343090

AN - SCOPUS:0020694075

VL - 19

SP - 123

EP - 126

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 1

ER -